JPND Call for Proposals: "A Sex and Gender Approach to Linking pre-diagnosis disturbances of physiological systems to Neurodegenerative Diseases"
Brain Canada is pleased to share a new funding opportunity for researchers. The European Union Joint Programme on Neurodegenerative Disease Research (JPND), a global research initiative with 30 member countries, has launched a transnational call for research on linking pre-diagnosis disturbances of physiological systems to neurodegenerative diseases. Brain Canada, Women’s Brain Health Initiative (WBHI) and Canadian Institutes of Health Research (CIHR) will be funding up to three Canadian research teams. Funds from Brain Canada and WBHI will go towards research projects that include sex and gender-based analysis. The total funding for this opportunity is $999,000.
Integrating a sex and gender lens in research will improve the way health interventions are designed, measured, analyzed, reported and implemented. Research approaches that consistently account for sex and gender drive innovation and scientific rigour, while also reducing gender-based health inequities for previously underrepresented voices. By partnering with WBHI, and funding projects that effectively address sex and gender differences, Brain Canada aims to support research that is generalizable to everyone and will ultimately enable the development of new diagnostics or interventions for a more diverse group of patients with neurodegenerative diseases.
This transnational call invites proposals for ambitious, innovative, multinational and multidisciplinary collaborative research projects with a view to promoting research aimed at the detection, measurement and understanding of early disease indicators related to neurodegenerative diseases, with potential for the development of new diagnostics or interventions.
Proposals may be submitted by research groups working in universities (or other higher education institutions), non-university public or private research organisations, hospitals and other health and social care settings, as well as commercial companies, in particular small and medium-size enterprises(SMEs). Collaborations with companies from outside the traditional medicalsector (e.g.computing, artificial intelligence) are welcome. With regard to the research setting and collaborations with companies, specific regulations of individual funding organisationsas well as the EU State aid regulations must be consideredwhen creating the consortium.